Summary: This study aimed to assess the steady-state pharmacokinetics of pranlukast, a leukotriene receptor antagonist, in children with allergic rhinitis and bronchial asthma, and to clarify factors aŠect-ing apparent clearance (CL W F). A total of 192 plasma samples were obtained from 98 children (rhinitis 64, asthma 13, complications 21), aged 3-14 years in 2 clinical trials. Plasma concentration of pranlukast was determined by liquid chromatography connected with a tandem mass spectrometer and analyzed by a population approach using NONMEM program. The plasma concentration-time course of pranlukast was described by using a one-compartment model with theˆrst-order absorption and lag time. The robustness of the population pharmacokinetic model was evaluated by using 200 bootstrap samples. The results of population pharmacokinetic analysis showed that only age was a factor aŠecting the CL W F per body weight, with CL W F decreasing with increasing age. No signiˆcant variation was seen in the CL W F between rhinitis and asthma. The interindividual variability in the CL W F and the residual variability were 19.7z and 48.4z, respectively. All the parameters fell within 10z of the bootstrapped mean.
Introduction
Pranlukast is an oral leukotriene receptor antagonist that is being developed as dry syrup for children with allergic rhinitis. [1] [2] [3] The proportional of pediatric patients with allergic rhinitis is assumed to be approximately 30z out of 18 to 23 million patients estimated in Japan. The main symptoms of allergic rhinitis include sneezing, nasal discharge, and nasal congestion. Of these symptoms, nasal congestion is the most uncomfortable symptom in children with allergic rhinitis, and it has been reported that the symptom impairs the quality of life in more than 80z of pediatric patients. 4) Pranlukast is characterized by the potent eŠect on nasal congestion compared with the existing antiallergic agents in adult patients with perennial allergic rhinitis, 5) and it is expected to be eŠective in pediatric patients as well.
Pranlukast has been already applied clinically in children with bronchial asthma in Japan. Pranlukast is mainly metabolized by CYP3A in vitro and is hardly excreted in urine of adults. We have already performed a population pharmacokinetic analysis on children with asthma and reported that the apparent clearance (CL W F) was about 1.6 times higher in pediatric patients than in adult patients. 6) However, there has been no report on the pharmacokinetics of pranlukast in children with allergic rhinitis. This study aimed to assess the pharmacokinetics of pranlukast in children with allergic rhinitis and to clarify factors aŠecting the pharmacoki- netics of this drug, including diŠerences in underlying diseases.
Methods

Study designs:
The studies in children with allergic rhinitis (Study 1) and in children with bronchial asthma (Study 2) 6) were conducted according to two similar protocols. Pranlukast hydrate dry syrup was orally administered twice a day at a dose range of 5.5 to 8.3 mg W kg W day. Study 1 enrolled children with perennial and W or seasonal allergic rhinitis aged 4-14 years. In principle, blood samples were collected once each at weeks 12 and 24 after starting drug administration, and sampling points were decided on any two of the following three time points: 1-3 h, 3-6 h, or 6-10 h after administration. Study 2 enrolled asthmatic children aged 3-14 years. Blood samples were collected at 2 time points of 4-6 h and 8-10 h after dosing at least 1 week from starting administration. The third sampling was performed 1-3 h after administration whenever possible. The number of blood sampling per visit on both Study 1 and 2 was decided once due to the limitation of study conducting.
The study protocols were reviewed and approved by the Institutional Review Boards of each clinical study site. Written informed consent was obtained from parents or legal guardians of all children. In addition, informed assent was obtained from children over eight years old.
Patient population: Table 1 summarizes demographic background for the population participating in the present analysis. A total of 98 patients were enrolled in the analysis, i.e., 76 cases in Study 1 and 22 cases in Study 2. The study population comprised 70 males and 28 females. The age ranged from 3 to 14 years old, with the median age of 9 years old. Twenty one patients had complications of allergic rhinitis and bronchial asthma. Theophylline was used in 20 cases, and abnormal values of total bilirubin were observed in 4 patients. A total of 192 drug concentration measurements were used for the population pharmacokinetic analysis.
Assay of pranlukast concentrations: Plasma concentration of pranlukast was determined by liquid chromatography connected with a tandem mass spectrometer (LC W MS W MS). Pranlukast was extracted from plasma by liquid-liquid extraction with 0.3 mol W L potassium dihydrogen phosphate solution and ethyl acetate, and then the organic layer was evaporated to dryness; the obtained residue was dissolved in the mobile phase, followed by being injected into the LC W MS W MS system. The linear range was 2 to 200 ng W mL, with the lower limit of quantitation being 2 ng W mL. The methods were validated for accuracy, precision, sensitivity, and speciˆcity.
Data analysis: The software NONMEM program (Ver.V level 1.1) was used to obtain the population means of pharmacokinetic parameters, interindividual variabilities in these parameters, and residual variability between the observed and the predicted pranlukast concentrations. The concentration-time course of pranlukast was presented by using a one-compartment model with theˆrst-order absorption and lag time. The pharmacokinetics of pranlukast was described by the following equation (1):
where C ij is the plasma concentration measured in the jth subject at the ith time point (tij). Dj and CLj are the dose and total body clearance in the jth subject, respectively. Vd W F and tlag are an apparent volume of distribution and lag time of absorption, respectively. Ka is thê rst order absorption rate constant, and wasˆxed to 0.493 h -1 which was estimated in a previous study. 6) This may be caused by relatively high variability of plasma concentration in the absorption phase and by lack of data points to estimate Ka. However, the variability of tlag seemed to be lower than that of Ka. Additionally, the tlag of 0.981 h in our previous study was thought to be a little longer compared to the actual data. Therefore, tlag was decided to be estimated. The interindividual variability in CL was modelled with the proportional error model according to the following equation (2):
where CL j is the total body clearance for the jth individual, CLj is the jth individual parameter with the regression model, and hj is the independently distributed random variable with mean zero and variance v 2 . It was determined impossible to estimate the interindividual variabilities in Vd and t lag since the estimated values were very low.
The intraindividual residual variability was also modelled with the proportional error model according to the following equation (3):
where Cij is the ith measured plasma concentration in the jth subject, Cij is the corresponding predicted plasma concentration, and eij is residual variability terms, representing independent identically distributed statistical errors with mean zero and variance s 2 . The proportional error model was statistically most signiˆcant in the additive, proportional, and mixed error model.
To test the signiˆcance of various factors aŠecting the pharmacokinetic parameters, we used the value of objective function determined in the NONMEMˆtting routine. DiŠerences in objective function values obtained by comparing each model are asymptotically distributed as chi-square with degree of freedom equal to the diŠerence in the number of parameters between the two models. To identify potentially signiˆcant factors, diŠerences in the objective function associated with a P value of º0.05 were required.
Bootstrap validation: The accuracy and robustness of theˆnal model were assessed by using a bootstrap method. 7) Two hundred data sets were reconstructed by resampling from the original data. The mean parameter estimates obtained from 200 bootstrap replications were compared with those obtained from the original data set. Figure 1 shows the plasma concentrations of pranlukast used for the population pharmacokinetic analysis. A one-compartment model with theˆrst-order absorption and lag time was used as a simple model, and the eŠect of age was initially tested by the model which treated age as a discrete or continuous variable. In the discrete function, age was categorized as 3 to 6 years old (infants) or 7 to 14 years old (schoolchildren). Whereas in the continuous function, CL W F was postulated to change linearly (linear model) or non-linearly (multiplicative model) according to increasing age. As shown in Table 2 , all models were signiˆcant, and the model in which CL W F decreased linearly according to increasing age was the most signiˆcant. Next, covariates aŠecting the pharmacokinetics of pranlukast were explored by the model including the eŠect of age as the basic model. The following clinical factors as covariates were tested individually: gender, concomitant medication of theophylline, and total bilirubin. As shown in Table 3 , none of these clinical factors was found to in‰uence GEND was designated 0 in males, and 1 in females. Other factors were designated 1 in the case of being factor. The interindividual variability in CL W F was 19.7z and the residual variability was 48.7z.
Results
In order to conˆrm that theˆnal model actually re‰ects the observed plasma concentrations, the predicted values obtained by Bayesian estimation are plotted versus the observed values in Fig. 2 and weight- ed residual plots for theˆnal model are shown in Fig. 3 . The values were generally distributed around zero and were relatively symmetric. No obvious bias pattern was apparent in the plot of the predicted concentration versus the weighted residual. Table 5 lists the parameter estimates of theˆnal model and the results of the bootstrap validation step. As a result of analyzing 200 bootstrap samples, 194 samples were converged. All structural parameters (u) and the variance parameters (v, s) were within 10z of the bootstrapped mean out of the 194 samples. Figure 4 shows the relationship between age and CL W F calculated by Bayes estimation for each individual patient. The population mean plasma concentrationtime proˆles of pranlukast in pediatric patients aged 3, 7, and 14 years are illustrated in Fig. 5 , where age 3 and 14 mean the lower and upper limit of age range of the patients tested, respectively, and age 7 means the minimum age for schoolchildren. A reduction of CL W F and an increase in pranlukast plasma concentration according to increasing age were observed, and estimated the CL W F was 1.77, 1.47 and 0.944 L W h W kg, respectively, in patients aged 3, 7 and 14 years.
Discussion
Our previous study reported that CL W F per body weight of pranlukast was about 1.6 times higher in children than in adults from the results obtained in combined population pharmacokinetic analysis of data from pediatric patients and adult patients. However, no changes were found in CL W F associated with age in pediatric patients in the previous study. 6) This was attributed to the fact that age of pediatric patients could not be treated as a continuous variable because of the small sample size of children (22 subjects and 54 blood samplings). The present study combined the two studies and the number of data points increased by more than 3 times compared to the previous study. This was why age could be treated as a continuous variable in pediatric patients and changes in CL W F associated with age of patients could be described in this study. The present study conˆrmed a linear relationship between the CL W F of pranlukast and the age of pediatric patients. Taking the CL W F at 14 years (0.944 LW h W kg) as the base value, we obtained the relational expression in which the CL W F increased by 0.0753 L W h W kg per year decrease in age. In addition, the CL W F of adults calculated from the dose and the AUC in the labeling was 0.922 L W h W kg and the CL W F of 14 years corresponded to this well. Since pranlukast is primarily metabolized in the liver, it was considered that the decrease in the clearance of this drug according to increasing age resulted from the reduction of liver weight per body weight due to growing up. 8) Furthermore, it was unlikely that aged-related diŠer-ences in the activity of metabolic enzymes aŠected the clearance. Because the activity of CYP3A4, the main metabolic enzyme of pranlukast, per mg protein has been reported to reach the same level as in adults after theˆrst year of life. 9, 10) Whereas, the absorption rate constant of Ka was 0.493 h -1 and the elimination rate constant of 3 and 14 years calculated with CL W F and Vd in this study was 0.886 and 0.472 h -1 , respectively. Consequently, ‰ip-‰op phenomenon is caused depend on age, thus, whether age aŠects CL W F or other pharmacokinetic parameters is not necessarily obvious. On the other hand, pranlukast is mainly metabolized in the liver and CL W F of 14 years old and adults corresponded well as mentioned above, the pharmacokinetic model that age aŠecting CL W F was considered to be appropriate.
While there are some studies that reported the pharmacokinetics of antiallergic drugs including ketotifen, 11) montelukast, 12) and epinastine 13) in children, there is no report comparing the pharmacokinetics between asthmatic patients and patients with allergic rhinitis. This is theˆrst study showing that the diŠerence of disease type does not aŠect the pharmacokinetics in pediatric patients. There was no diŠerence in the pharmacokinetics of pranlukast between the two conditions because of the following reasons: asthma and allergic rhinitis are similar in‰ammatory diseases with in‰ammatory reaction in the upper and lower respiratory tracts, 14) and neither of the two diseases is a pathophysiological condition that aŠects the pharmacokinetics of this drug except for at asthmatic attack.
The Ka value used was obtained in the previous study 6) as mentioned in the Methods. In order to test eŠects ofˆxed Ka value on CL W F, CL W F was estimated using theˆnal model if Ka was set to be one-third or threefold of theˆxed. As a result, CL W F was hardly aŠected even by Ka variance. Wade et al. had reported that a misspeciˆcation would have not large eŠect on estimation of CL W F, the same as our conclusion. 15) From the above results, it was judged that the analytical results were aŠected little byˆxing the value of Ka to the value previously reported.
Di‹culty inˆtting plasma concentration-time proˆle of pranlukast to compartment models would be one of the reasons for indicating high residual variability. Pranlukast has low solubility and relatively short elimination half life, even its 1.5 hours in adults (labeling data). As such these pharmacokinetic properties, the plasma concentration-time proˆle for adults shows symmetric close-ˆgure with the maximum concentration centered, and this proˆle leaded to a model error. Moreover, this residual variability includes interoccasional variability and this may be also the other reasons. Since the sampling design in this study was once per visit due to the limitation of study conducting, it was impossible to separate intraindividual variability and interoccasional variability. However, the parameter estimates on bootstrap samples corresponded to the original data well. In addition, a convergence ratio on bootstrap data was extremely high, the stability of this model was guaranteed. Moreover, the CL W F of 14 years estimated by this model and that of adults in the labeling likely to correspond, thus the in‰uence to the age for CL W F is considered to be evaluated appropriately. Consequently, high residual variability in this study could not cause undesirable in‰uence to an interpretation of the analytical results.
In conclusion, a population pharmacokinetics model for pranlukast in children with allergic rhinitis and bronchial asthma was developed and it was shown that this model was stable by bootstrap validation. The model shows that age is the most in‰uential factor for explaining interindividual variability in CL W F, and the diŠerence in diseases does not aŠect CL W F.
